title: FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
abstract: OBJECTIVE
  The role of FDG-PET in primary central nervous system lymphoma (PCNSL) is unclear. It was the aim of this study to investigate the role of FDG-PET in detecting PCNSL and in predicting response to chemotherapy.
  
  
  METHODS
  An FDG-PET scan of the brain was performed in 15 patients with histologically proven PCNSL (16 PET examinations, Siemens ECAT EXACT). PET was planned to investigate patients at the time of primary diagnosis, after chemotherapy and at the time of suspected relapse in seven, five and three cases, respectively. All except two patients simultaneously underwent MRI of the brain. FDG-PET results were correlated with histological results after stereotactic biopsy (primary diagnosis group) and with clinical data and MRI during follow-up.
  
  
  RESULTS
  Six of the seven patients in the primary diagnosis group demonstrated a true positive finding (86%). In one of the true positive PET patients, there were two tumour lesions, one of which was only detectable on the FLAIR MRI sequence. In five patients, FDG-PET showed no sign of PCNSL during ongoing chemotherapy. These results were confirmed by the clinical follow-up (mean 26.6 months). MRI demonstrated minimal residual disease which had disappeared on further follow-up MRI in three of these five patients at the time of PET scanning. Recurrence of disease was confirmed concordantly by FDG-PET and MRI in three different patients. The standardised uptake value of all tumours was 10.2 (4.3-13.7).
  
  
  CONCLUSIONS
  PCNSLs demonstrate high FDG uptake and can be diagnosed by FDG-PET with high sensitivity. It seems that FDG-PET is suitable for early therapeutic monitoring after chemotherapy.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. holger.palmedo@ukb.uni-bonn.de
authors.forename: H
authors.initials: H
authors.lastname: Palmedo
authors.forename: H
authors.initials: H
authors.lastname: Urbach
authors.forename: H
authors.initials: H
authors.lastname: Bender
authors.forename: U
authors.initials: U
authors.lastname: Schlegel
authors.forename: I G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
authors.forename: A
authors.initials: A
authors.lastname: Matthies
authors.forename: M
authors.initials: M
authors.lastname: Linnebank
authors.forename: A
authors.initials: A
authors.lastname: Joe
authors.forename: J
authors.initials: J
authors.lastname: Bucerius
authors.forename: H-J
authors.initials: HJ
authors.lastname: Biersack
authors.forename: H
authors.initials: H
authors.lastname: Pels
mesh_terms: D000368:Aged; D016543:Central Nervous System Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008223:Lymphoma / Q000175:diagnosis* / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18